The epidemiology and burden of respiratory syncytial virus and influenza infections in hospitalized children under 5 years old in Zhejiang, China (2018–2023)

Wanwan Sun, Qiuyao Duan, Lei Guo, An Zhu, An Tang, Ziping Miao, Yingxin Zhang, Yuan Fen, Xiaofei Fu, Shengliang Shi, Lan Wang, Shijian Li, Xiaolu Xu, Chunlei Zhu, Lefei Zhou, Rui Li, Yue Pang, Yu Zhao, Jinren Pan, Chaorong Ni, Shelan LiuFrontiers in Public Health 2025 · DOI

TL;DR

This study quantifies the massive hospital burden of Respiratory Syncytial Virus (RSV) compared to influenza in young children in Zhejiang, China, revealing that RSV causes three times more hospitalizations and significantly higher rates of pneumonia. The research also highlights a dramatic "immunity debt" caused by COVID-19 interventions, which led to a 526% surge in RSV hospitalizations and a shift toward older patients once social restrictions were lifted.

What Problem Does This Paper Address?

While both RSV and influenza are major drivers of pediatric respiratory illness, comparative data on their relative "burden"—including hospitalization costs, duration, and clinical severity—has been limited in mainland China. Furthermore, the non-pharmaceutical interventions (NPIs) used to combat COVID-19 (like masking and social distancing) fundamentally disrupted the transmission of other respiratory viruses.

The authors sought to understand how the epidemiology of these two viruses evolved between 2018 and 2023. By comparing pre-pandemic data with the post-pandemic "resurgence" period, they aimed to provide a roadmap for public health priorities, specifically regarding the urgency of pediatric vaccination and monoclonal antibody treatments.

Methods

The researchers conducted a multicenter retrospective cohort study across eight hospitals in Zhejiang Province, covering approximately 75% of the local population.

  • Study Population: Hospitalized children under 5 years old who tested positive for RSV or influenza (A or B) via RT-PCR or rapid antigen tests.
  • Temporal Comparison: The study divided data into "pre-pandemic" (Jan 2018 – Dec 2019) and "post-pandemic" (Jan 2020 – Aug 2023) phases.
  • Statistical Analysis: Beyond standard descriptive statistics, the team used multivariate logistic regression to calculate Odds Ratios (OR) and 95% Confidence Intervals (CI). This allowed them to isolate the specific risks associated with RSV versus influenza while controlling for variables like age, gender, and underlying conditions.

Datasets

The study utilized a primary clinical dataset of 10,428 hospitalized children:

  • 7,857 RSV infections
  • 2,571 influenza infections

Data was extracted from anonymized electronic medical records and Hospital Information Systems (HIS), including demographic info, clinical outcomes, and detailed hospitalization costs (in RMB).

Key Insights and Ideas

  • RSV Outweighs Influenza: In this pediatric cohort, RSV was the dominant threat. It was responsible for nearly three times as many hospitalizations as influenza and carried a much higher risk of progressing to pneumonia (81% vs 40%).
  • The "Immunity Debt" Phenomenon: During the height of COVID-19 NPIs, RSV and flu cases plummeted. This created a cohort of "immunologically naive" children. When restrictions eased, the viruses didn't just return; they surged. RSV hospitalizations increased by over 526% compared to pre-pandemic levels.
  • Age Shift: Post-pandemic, the median age for RSV infection shifted from ~10 months to ~17 months. This suggests that toddlers who missed their "natural" infant exposure due to lockdowns were hitting the hospital system all at once later in life.
  • Economic Paradox: While the total volume of cases exploded post-pandemic, the average cost and duration per hospitalization actually decreased slightly. The authors hypothesize that improved diagnostic speed (wider use of PCR) and a shift toward slightly older, more resilient children may have contributed to this.

Key Results

  • Clinical Severity: RSV patients had significantly longer hospital stays (mean 5.66 vs. 5.04 days) and higher costs (mean 5,616 RMB vs. 5,352 RMB) than influenza patients.
  • Risk Ratios: Compared to influenza, RSV infection was associated with a 5.8x higher risk of pneumonia.
  • Vulnerability Window: The highest risk for RSV hospitalization was found in the 6–12 month age group (OR = 23.1 compared to influenza).
  • Seasonality Disruption: The traditional winter peaks for these viruses were disrupted. RSV, for instance, saw a massive delayed peak in the spring and summer of 2023.

Limitations and Future Work

The authors acknowledge several limitations:

  • Admission Bias: Criteria for hospital admission can vary between the eight different facilities.
  • Missing Genomic Data: The study did not track specific viral genotypes or strains, which could influence severity.
  • Socioeconomic Factors: Indirect costs (like parents' lost wages) and family economic status were not captured, potentially underestimating the true societal burden.

Future Work: The authors urge the integration of the newly approved monoclonal antibody Nirsevimab and increased influenza vaccine coverage to mitigate these burdens. They also suggest that future studies should focus on the specific biological mechanisms behind the "immunity debt" to better predict future off-season surges.

Summary updated

Abstract

RSV is a significant contributor to disease burden in hospitalized children under 5 years old, outweighing influenza. The COVID-19 pandemic impacted the epidemiological characteristics and disease burden of hospitalization for RSV and influenza infections. A more effective prevention strategy for both infections in young children, especially vaccinations against RSV and influenza, is urged.
BibTeX
@inproceedings{sun2025epidemiology,
  author = {Wanwan Sun and Qiuyao Duan and Lei Guo and An Zhu and An Tang and Ziping Miao and Yingxin Zhang and Yuan Fen and Xiaofei Fu and Shengliang Shi and Lan Wang and Shijian Li and Xiaolu Xu and Chunlei Zhu and Lefei Zhou and Rui Li and Yue Pang and Yu Zhao and Jinren Pan and Chaorong Ni and Shelan Liu},
  title = {{The epidemiology and burden of respiratory syncytial virus and influenza infections in hospitalized children under 5 years old in Zhejiang, China (2018–2023)}},
  booktitle = {Frontiers in Public Health},
  year = {2025},
  doi = {10.3389/fpubh.2025.1470770},
}
Figure